Pricing Log in Create free account

Beam Therapeutics Inc. (BEAM) vs SELLAS Life Sciences Group, Inc. (SLS)

Beam Therapeutics Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Beam Therapeutics Inc. is the larger, with a market value of $2.6B against $2.3B — 1.1× the size. SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −55.5%) and the higher return on invested capital (0.00% vs −1,599.3%). Across the 16 metrics below, SELLAS Life Sciences Group, Inc. leads on 9 and Beam Therapeutics Inc. on 7.

Valuation

Metric BEAM SLS Biotechnology median
P/E n/m n/m 8.50
P/S 15.69 179.81 9.71
P/B 2.29 13.72 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.95 166.67 9.21
Earnings yield (3.49%) (2.10%) (33.15%)
Free cash flow yield (15.22%) (2.04%) (25.50%)

Profitability

Metric BEAM SLS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (242.27%) 0.00% 0.00%
Net margin (55.45%) 0.00% 0.00%
Free cash flow margin (238.90%) 0.00% 0.00%
Return on equity (8.18%) (39.63%) (56.36%)
Return on assets (6.23%) (36.54%) (48.04%)
Return on invested capital (1,599.30%) 0.00% 0.00%

Growth

Metric BEAM SLS Biotechnology median
Revenue growth (TTM) 158.88% — 6.02%
EPS growth (last fiscal year) 82.31% 50.00% 30.26%
Revenue growth, 5-year CAGR 466.27% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BEAM SLS Biotechnology median
Debt to equity 0.09 0.00 0.00
Current ratio 14.57 18.83 4.72
Net debt to EBITDA 3.30 2.54 0.96

Dividend

Metric BEAM SLS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BEAM SLS Biotechnology median
Market cap 2.55b 2.29b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack